Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003600 · ClinicalTrials.gov registry record · Phase 3
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT00003600 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 344 participants.
The verdict
NCT00003600, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy. It is not yet known whether epoetin alfa is more effective than a placebo in treating anemia in patients receiving chemotherapy. PURPOSE: Randomized double blinded phase III trial to compare the effectiveness of epoetin alfa with a placebo in treating anemia in cancer patients who are receiving chemotherapy.
Interventions
- OTHER placebo
- BIOLOGICAL epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 1998-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003600
The ClinicalTrials.gov registry entry for NCT00003600 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00003600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003600 about?
NCT00003600 is a clinical study titled "Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy". RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy. It is not yet known whether epoetin alfa is more effective than a placebo in treating anemia in patients receiving chemotherapy. PURPOSE: Randomized double blinde...
What is the current status of trial NCT00003600?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 1998-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00003600?
The interventions under investigation include: placebo (OTHER), epoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003600?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.